Rejuvenation Roundup September 2024

In the research world, things are not always as expected.

This past month, we’ve covered plenty of research news and information about conferences, but now we have some news of our own. Here’s what’s been happening in the rejuvenation biotechnology world.

LEAF News

Lifespan.io and SENS Research Foundation Unite to Launch a New Powerhouse in Aging Research: Today, we and SENS Research Foundation are excited to announce the completion of their merger, forming a new 501(c)(3) non-profit: Lifespan Research Institute.

Interviews

I Dined with Bryan Johnson and Didn’t Die: Don’t Die is a concept or philosophy that Bryan has been developing. It shares some premises with Ray Kurzweil’s theory of singularity, which states that due to the ever-increasing pace of technological progress, a future is near that is completely unimaginable – and hence, unpredictable from our current standpoint.

Advocacy and Analysis

NILAR: A4LI’s Response to NIH Reform Proposal: The longevity advocacy and lobbying group has submitted detailed feedback to the congressional proposal to replace NIA with the National Institute on Dementia – and now you can sign the petition.

Less Talk, More Work: Foresight/LBF Longevity Workshop 2024: When Foresight Institute and Longevity Biotech Fellowship joined forces, a one-of-a-kind longevity event emerged. Foresight Institute has been perfecting the workshop formula for years. According to Foresight CEO Allison Duettmann, it’s been quite successful, with numerous ideas, which were originally thrown around at workshops, becoming projects and getting funded.

News Nuggets

Ora Biomedical Awarded Technology Development Grant: Ora Biomedical, Inc., a pioneering longevity biotechnology company, is pleased to announce that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Institutes of Health (NIH). The $324,240 grant will support the development of EleGantry, an innovative software and hardware infrastructure to improve research quality.

Insilico Medicine Reports Positive Phase IIa Results for IPF: Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced positive preliminary results from its Phase IIa clinical trial evaluating ISM001-055. ISM001-055 is a first-in-class small molecule targeting TNIK (Traf2- and Nck-interacting kinase) and was designed utilizing generative AI to treat idiopathic pulmonary fibrosis (IPF).

Learn More on Lifespan.io...